Shell Companies
Compare Stocks
5 / 10Stock Comparison
DMAA vs HCAI vs IIPR vs APCX vs REFI
Revenue, margins, valuation, and 5-year total return — side by side.
Industrial - Machinery
REIT - Industrial
Software - Infrastructure
REIT - Mortgage
DMAA vs HCAI vs IIPR vs APCX vs REFI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Shell Companies | Industrial - Machinery | REIT - Industrial | Software - Infrastructure | REIT - Mortgage |
| Market Cap | $111M | $13M | $1.64B | $14M | $252M |
| Revenue (TTM) | $0.00 | $41M | $263M | $787K | $60M |
| Net Income (TTM) | $6M | $1M | $120M | $-7M | $31M |
| Gross Margin | — | 14.0% | 60.3% | 57.1% | 93.9% |
| Operating Margin | — | 5.5% | 46.7% | -10.0% | 25.3% |
| Forward P/E | — | 8.0x | 13.5x | — | 6.5x |
| Total Debt | $662.00 | $12M | $394M | $147K | $98M |
| Cash & Equiv. | $1K | $29K | $48M | $868K | $15M |
DMAA vs HCAI vs IIPR vs APCX vs REFI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Feb 25 | May 26 | Return |
|---|---|---|---|
| Drugs Made In Ameri… (DMAA) | 100 | 106.3 | +6.3% |
| Hauchen AI Parking … (HCAI) | 100 | 8.7 | -91.3% |
| Innovative Industri… (IIPR) | 100 | 79.6 | -20.4% |
| AppTech Payments Co… (APCX) | 100 | 94.7 | -5.3% |
| Chicago Atlantic Re… (REFI) | 100 | 74.3 | -25.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DMAA vs HCAI vs IIPR vs APCX vs REFI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, DMAA doesn't own a clear edge in any measured category.
HCAI has the current edge in this matchup, primarily because of its strength in growth exposure and sleep-well-at-night.
- Rev growth 19.4%, EPS growth -4.2%, 3Y rev CAGR 69.2%
- Lower volatility, beta 0.34, Low D/E 41.5%, current ratio 2.58x
- 19.4% revenue growth vs APCX's -45.2%
- Beta 0.34 vs APCX's 1.27
IIPR is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 439.9% 10Y total return vs REFI's 26.7%
- 13.3% yield, 9-year raise streak, vs REFI's 17.1%, (3 stocks pay no dividend)
- 5.1% ROA vs APCX's -115.0%, ROIC 4.3% vs -183.2%
APCX is the clearest fit if your priority is momentum.
- +45.3% vs HCAI's -94.7%
REFI ranks third and is worth considering specifically for income & stability and defensive.
- Dividend streak 0 yrs, beta 0.70, yield 17.1%
- Beta 0.70, yield 17.1%, current ratio 0.28x
- Better valuation composite
- 51.8% margin vs APCX's -9.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.4% revenue growth vs APCX's -45.2% | |
| Value | Better valuation composite | |
| Quality / Margins | 51.8% margin vs APCX's -9.1% | |
| Stability / Safety | Beta 0.34 vs APCX's 1.27 | |
| Dividends | 13.3% yield, 9-year raise streak, vs REFI's 17.1%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +45.3% vs HCAI's -94.7% | |
| Efficiency (ROA) | 5.1% ROA vs APCX's -115.0%, ROIC 4.3% vs -183.2% |
DMAA vs HCAI vs IIPR vs APCX vs REFI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
DMAA vs HCAI vs IIPR vs APCX vs REFI — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HCAI leads in 1 of 6 categories
IIPR leads 1 • REFI leads 1 • DMAA leads 1 • APCX leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — IIPR and APCX and REFI each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IIPR and DMAA operate at a comparable scale, with $263M and $0 in trailing revenue. REFI is the more profitable business, keeping 51.8% of every revenue dollar as net income compared to APCX's -9.1%. On growth, APCX holds the edge at +4.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $41M | $263M | $787,000 | $60M |
| EBITDAEarnings before interest/tax | -$726,546 | — | $197M | -$7M | $15M |
| Net IncomeAfter-tax profit | $6M | — | $120M | -$7M | $31M |
| Free Cash FlowCash after capex | -$414,132 | — | $144M | -$7M | $24M |
| Gross MarginGross profit ÷ Revenue | — | +14.0% | +60.3% | +57.1% | +93.9% |
| Operating MarginEBIT ÷ Revenue | — | +5.5% | +46.7% | -10.0% | +25.3% |
| Net MarginNet income ÷ Revenue | — | +3.7% | +45.6% | -9.1% | +51.8% |
| FCF MarginFCF ÷ Revenue | — | +3.7% | +54.7% | -8.7% | +40.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -72.8% | -3.8% | +4.3% | +16.3% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -62.7% | -1.0% | +34.8% | -51.1% |
Valuation Metrics
HCAI leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 7.1x trailing earnings, REFI trades at a 51% valuation discount to IIPR's 14.6x P/E. On an enterprise value basis, HCAI's 8.0x EV/EBITDA is more attractive than DMAA's 9999.0x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $111M | $13M | $1.6B | $14M | $252M |
| Enterprise ValueMkt cap + debt − cash | $111M | $25M | $2.0B | $13M | $336M |
| Trailing P/EPrice ÷ TTM EPS | -189.29x | 8.03x | 14.58x | -1.13x | 7.12x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 13.49x | — | 6.50x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 3.89x | — | — |
| EV / EBITDAEnterprise value multiple | 9999.00x | 7.96x | 10.01x | — | 9.32x |
| Price / SalesMarket cap ÷ Revenue | — | 0.32x | 6.16x | 49.58x | 4.00x |
| Price / BookPrice ÷ Book value/share | — | 0.43x | 0.88x | 1.84x | 0.83x |
| Price / FCFMarket cap ÷ FCF | — | 8.63x | 9.37x | — | 8.76x |
Profitability & Efficiency
IIPR leads this category, winning 3 of 9 comparable metrics.
Profitability & Efficiency
IIPR delivers a 6.4% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-5 for APCX. APCX carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to HCAI's 0.42x. On the Piotroski fundamental quality scale (0–9), HCAI scores 7/9 vs DMAA's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +5.5% | +6.4% | -5.1% | +0.0% |
| ROA (TTM)Return on assets | +2.4% | +3.0% | +5.1% | -115.0% | +0.0% |
| ROICReturn on invested capital | — | +4.2% | +4.3% | -183.2% | +6.9% |
| ROCEReturn on capital employed | — | +7.0% | +5.8% | -194.5% | +9.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 | 4 | 5 | 4 |
| Debt / EquityFinancial leverage | — | 0.42x | 0.21x | 0.03x | 0.32x |
| Net DebtTotal debt minus cash | $661 | $12M | $346M | -$721,000 | $83M |
| Cash & Equiv.Liquid assets | $1,351 | $28,654 | $48M | $868,000 | $15M |
| Total DebtShort + long-term debt | $662 | $12M | $394M | $147,000 | $98M |
| Interest CoverageEBIT ÷ Interest expense | — | 4.00x | 6.67x | -10.21x | 4.77x |
Total Returns (Dividends Reinvested)
REFI leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in REFI five years ago would be worth $12,674 today (with dividends reinvested), compared to $1,042 for HCAI. Over the past 12 months, APCX leads with a +45.3% total return vs HCAI's -94.7%. The 3-year compound annual growth rate (CAGR) favors REFI at 8.6% vs HCAI's -52.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +2.1% | +33.8% | +19.6% | +20.2% | +1.4% |
| 1-Year ReturnPast 12 months | +5.0% | -94.7% | +16.6% | +45.3% | -6.8% |
| 3-Year ReturnCumulative with dividends | +6.4% | -89.6% | +15.1% | -80.1% | +28.2% |
| 5-Year ReturnCumulative with dividends | +6.4% | -89.6% | -46.9% | -80.2% | +26.7% |
| 10-Year ReturnCumulative with dividends | +6.4% | -89.6% | +439.9% | +396.0% | +26.7% |
| CAGR (3Y)Annualised 3-year return | +2.1% | -52.9% | +4.8% | -41.6% | +8.6% |
Risk & Volatility
DMAA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DMAA is the less volatile stock with a 0.00 beta — it tends to amplify market swings less than APCX's 1.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DMAA currently trades 100.0% from its 52-week high vs HCAI's 3.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.00x | 0.34x | 0.91x | 1.27x | 0.70x |
| 52-Week HighHighest price in past year | $10.60 | $318.60 | $61.40 | $0.59 | $15.20 |
| 52-Week LowLowest price in past year | $10.09 | $0.32 | $44.58 | $0.06 | $10.74 |
| % of 52W HighCurrent price vs 52-week peak | +100.0% | +3.8% | +93.3% | +66.7% | +78.7% |
| RSI (14)Momentum oscillator 0–100 | 71.1 | 62.5 | 56.4 | 35.1 | 43.1 |
| Avg Volume (50D)Average daily shares traded | 166K | 1.5M | 297K | 39K | 171K |
Analyst Outlook
Evenly matched — IIPR and REFI each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: IIPR as "Hold", REFI as "Buy". Consensus price targets imply 47.8% upside for IIPR (target: $85) vs 42.1% for REFI (target: $17). For income investors, REFI offers the higher dividend yield at 17.10% vs IIPR's 13.30%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Hold | — | Buy |
| Price TargetConsensus 12-month target | — | — | $84.67 | — | $17.00 |
| # AnalystsCovering analysts | — | — | 11 | — | 6 |
| Dividend YieldAnnual dividend ÷ price | — | — | +13.3% | — | +17.1% |
| Dividend StreakConsecutive years of raises | — | — | 9 | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — | $7.62 | — | $2.05 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.2% | 0.0% | 0.0% |
HCAI leads in 1 of 6 categories (Valuation Metrics). IIPR leads in 1 (Profitability & Efficiency). 2 tied.
DMAA vs HCAI vs IIPR vs APCX vs REFI: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DMAA or HCAI or IIPR or APCX or REFI a better buy right now?
For growth investors, Hauchen AI Parking Management Technology Holding Co.
, Ltd. (HCAI) is the stronger pick with 19. 4% revenue growth year-over-year, versus -45. 2% for AppTech Payments Corp. (APCX). Chicago Atlantic Real Estate Finance, Inc. (REFI) offers the better valuation at 7. 1x trailing P/E (6. 5x forward), making it the more compelling value choice. Analysts rate Chicago Atlantic Real Estate Finance, Inc. (REFI) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DMAA or HCAI or IIPR or APCX or REFI?
On trailing P/E, Chicago Atlantic Real Estate Finance, Inc.
(REFI) is the cheapest at 7. 1x versus Innovative Industrial Properties, Inc. at 14. 6x. On forward P/E, Chicago Atlantic Real Estate Finance, Inc. is actually cheaper at 6. 5x.
03Which is the better long-term investment — DMAA or HCAI or IIPR or APCX or REFI?
Over the past 5 years, Chicago Atlantic Real Estate Finance, Inc.
(REFI) delivered a total return of +26. 7%, compared to -89. 6% for Hauchen AI Parking Management Technology Holding Co. , Ltd. (HCAI). Over 10 years, the gap is even starker: IIPR returned +439. 9% versus HCAI's -89. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DMAA or HCAI or IIPR or APCX or REFI?
By beta (market sensitivity over 5 years), Drugs Made In America Acquisition Corp.
Ordinary Shares (DMAA) is the lower-risk stock at 0. 00β versus AppTech Payments Corp. 's 1. 27β — meaning APCX is approximately Infinity% more volatile than DMAA relative to the S&P 500. On balance sheet safety, AppTech Payments Corp. (APCX) carries a lower debt/equity ratio of 3% versus 42% for Hauchen AI Parking Management Technology Holding Co. , Ltd. — giving it more financial flexibility in a downturn.
05Which is growing faster — DMAA or HCAI or IIPR or APCX or REFI?
By revenue growth (latest reported year), Hauchen AI Parking Management Technology Holding Co.
, Ltd. (HCAI) is pulling ahead at 19. 4% versus -45. 2% for AppTech Payments Corp. (APCX). On earnings-per-share growth, the picture is similar: AppTech Payments Corp. grew EPS 65. 3% year-over-year, compared to -28. 8% for Innovative Industrial Properties, Inc.. Over a 3-year CAGR, HCAI leads at 69. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DMAA or HCAI or IIPR or APCX or REFI?
Chicago Atlantic Real Estate Finance, Inc.
(REFI) is the more profitable company, earning 57. 1% net margin versus -32. 4% for AppTech Payments Corp. — meaning it keeps 57. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REFI leads at 57. 1% versus -34. 6% for APCX. At the gross margin level — before operating expenses — IIPR leads at 88. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DMAA or HCAI or IIPR or APCX or REFI more undervalued right now?
On forward earnings alone, Chicago Atlantic Real Estate Finance, Inc.
(REFI) trades at 6. 5x forward P/E versus 13. 5x for Innovative Industrial Properties, Inc. — 7. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IIPR: 47. 8% to $84. 67.
08Which pays a better dividend — DMAA or HCAI or IIPR or APCX or REFI?
In this comparison, REFI (17.
1% yield), IIPR (13. 3% yield) pay a dividend. DMAA, HCAI, APCX do not pay a meaningful dividend and should not be held primarily for income.
09Is DMAA or HCAI or IIPR or APCX or REFI better for a retirement portfolio?
For long-horizon retirement investors, Drugs Made In America Acquisition Corp.
Ordinary Shares (DMAA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 00)). Both have compounded well over 10 years (DMAA: +6. 4%, APCX: +396. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DMAA and HCAI and IIPR and APCX and REFI?
These companies operate in different sectors (DMAA (Financial Services) and HCAI (Industrials) and IIPR (Real Estate) and APCX (Technology) and REFI (Real Estate)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: DMAA is a small-cap quality compounder stock; HCAI is a small-cap high-growth stock; IIPR is a small-cap deep-value stock; APCX is a small-cap quality compounder stock; REFI is a small-cap high-growth stock. IIPR, REFI pay a dividend while DMAA, HCAI, APCX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.